Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 7:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 168 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oesophagitis, Eosinophilic Clear all
Completed No phase listed Observational

Prospective Analysis of Eosinophilic Esophagitis in Patients Presenting With Dysphagia

NCT00256529
View directory record Official record
Conditions
Esophagitis
Interventions
EGD with biopsies
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 90 Years
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 8, 2026, 7:08 AM EDT
Completed Phase 2 Interventional

Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis

NCT00123656
View directory record Official record
Conditions
Esophagitis
Interventions
esomeprazole, fluticasone
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 16, 2008 · Synced Oct 8, 2026, 7:08 AM EDT
Completed Phase 2 Interventional Results available

A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

NCT03496571
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Interventions
AK002, Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Ventura, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 8, 2026, 7:08 AM EDT
Completed No phase listed Observational

The Use of Fractionated Exhaled Nitric Oxide in the Diagnosis and Assessment of Disease Activity of Eosinophilic Esophagitis (Validation Phase)

NCT04941742
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
5 Years to 18 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 8, 2026, 7:08 AM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis

NCT00762073
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
budesonide, placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
2 Years to 18 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 8, 2026, 7:08 AM EDT
Completed Phase 2 Interventional Results available

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

NCT01808196
View directory record Official record
Conditions
Eosinophilic Esophagitis, Connective Tissue Disorders
Interventions
Losartan Potassium
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 8, 2026, 7:08 AM EDT
Completed Phase 2 Interventional

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

NCT02098473
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
RPC4046, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
27
States / cities
Scottsdale, Arizona • Tucson, Arizona • Oceanside, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 8, 2026, 7:08 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

NCT00635089
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
reslizumab
Drug
Lead sponsor
Ception Therapeutics
Industry
Eligibility
5 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 8, 2026, 7:08 AM EDT
Enrolling by invitation Early Phase 1 Interventional

Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.

NCT07358234
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT], budesonide oral suspension
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 8, 2026, 7:08 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Esophageal String Test in Eosinophilic Esophagitis

NCT02008903
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
7 Years to 65 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2027
U.S. locations
6
States / cities
Aurora, Colorado • Chicago, Illinois • Peoria, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 8, 2026, 7:08 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis

NCT01022970
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
QAX576 placebo, QAX576
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Stanford, California • Chicago, Illinois • Minneota, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 8, 2026, 7:08 AM EDT
Completed Phase 2 Interventional Results available

Mepo for Eosinophilic Esophagitis (EoE) Study

NCT03656380
View directory record Official record
Conditions
EoE, Eosinophilic Esophagitis
Interventions
Mepolizumab 300 mg, Mepolizumab 100 mg, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 8, 2026, 7:08 AM EDT
Completed Phase 3 Interventional

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

NCT05634746
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
59
States / cities
Dothan, Alabama • Mobile, Alabama • Scottsdale, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 8, 2026, 7:08 AM EDT
Not listed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

NCT02130882
View directory record Official record
Conditions
Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions
benralizumab, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 8, 2026, 7:08 AM EDT
Completed Not applicable Interventional

Sponge and Eosinophil Peroxidase (EPO) Staining

NCT03078023
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
swallowed sponge device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 8, 2026, 7:08 AM EDT
Completed Phase 4 Interventional Results available

Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis

NCT02371941
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
oral cromolyn sodium, Placebo
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
2 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 8, 2026, 7:08 AM EDT
Terminated Not applicable Interventional Results available

Cytosponge Protocol IRB 11-006429

NCT01585103
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Cytosponge
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 8, 2026, 7:08 AM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

NCT03633617
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
62
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 8, 2026, 7:08 AM EDT
Not listed No phase listed Observational

Fibrostenotic Eosinophilic Esophagitis: Assessment Tools

NCT02453126
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 8, 2026, 7:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Eating With Eosinophilic Esophagitis (EoE)

NCT03581838
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Observed eating session
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 8, 2026, 7:08 AM EDT
Completed Phase 2 Interventional Results available

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

NCT02379052
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Idaho Falls, Idaho • Chicago, Illinois • Urbana, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 8, 2026, 7:08 AM EDT
Completed No phase listed Observational

Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis

NCT02775045
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Observation Period
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 8, 2026, 7:08 AM EDT
Terminated Phase 2 Interventional Results available

Bethanechol for Eosinophilic Esophagitis

NCT02058537
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Bethanechol
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 22, 2016 · Synced Oct 8, 2026, 7:08 AM EDT
Active, not recruiting Phase 4 Interventional

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

NCT06101095
View directory record Official record
Conditions
Eosinophilic Oesophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 8, 2026, 7:08 AM EDT